Prime Medicine, Inc. Share-based Payment Arrangement, Expense
Prime Medicine, Inc. (PRME) reported Share-based Payment Arrangement, Expense of $4.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- Prime Medicine, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $4.87M, a 23.08% decline year-over-year.
- Prime Medicine, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $4.64M, a 18.25% decline year-over-year.
- Prime Medicine, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $4.51M, a 24.00% decline year-over-year.
- Prime Medicine, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $12.75M, a 86.71% increase year-over-year.
- Prime Medicine, Inc. share-based payment arrangement, expense for fiscal 2025 was $29.27M, a 12.28% increase from fiscal 2024.
- Prime Medicine, Inc. share-based payment arrangement, expense for fiscal 2024 was $26.07M, a 87.40% increase from fiscal 2023.
- Prime Medicine, Inc. share-based payment arrangement, expense for fiscal 2023 was $13.91M, a 115.36% increase from fiscal 2022.
- Prime Medicine, Inc. share-based payment arrangement, expense for fiscal 2022 was $6.46M, a 269.93% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.87M 10-Q · filed 2026-08-06 | $9.51M 10-Q · filed 2026-08-06 | $14.02M derived: sum of 3 quarters · filed 2026-08-06 | $26.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.64M 10-Q · filed 2026-05-07 | $9.16M derived: sum of 2 quarters · filed 2026-05-07 | $21.91M derived: sum of 3 quarters · filed 2026-05-07 | $28.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $17.26M derived: sum of 2 quarters · filed 2026-03-03 | $23.59M derived: sum of 3 quarters · filed 2026-08-06 | $29.27M 10-K · filed 2026-03-03 |
| 2025-09-30 | $12.75M 10-Q · filed 2025-11-07 | $19.07M derived: sum of 2 quarters · filed 2026-08-06 | $24.75M 10-Q · filed 2025-11-07 | $30.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.33M 10-Q · filed 2026-08-06 | $12.01M 10-Q · filed 2026-08-06 | $17.95M derived: sum of 3 quarters · filed 2026-08-06 | $24.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.68M 10-Q · filed 2026-05-07 | $11.62M derived: sum of 2 quarters · filed 2026-05-07 | $18.45M derived: sum of 3 quarters · filed 2026-05-07 | $26.54M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $12.77M derived: sum of 2 quarters · filed 2026-03-03 | $20.86M derived: sum of 3 quarters · filed 2026-03-03 | $26.07M 10-K · filed 2026-03-03 |
| 2024-09-30 | $6.83M 10-Q · filed 2025-11-07 | $14.92M derived: sum of 2 quarters · filed 2025-11-07 | $20.13M 10-Q · filed 2025-11-07 | $24.56M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $8.09M 10-Q · filed 2025-08-07 | $13.30M 10-Q · filed 2025-08-07 | $17.73M derived: sum of 3 quarters · filed 2025-08-07 | $21.95M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $5.21M 10-Q · filed 2025-05-08 | $9.64M derived: sum of 2 quarters · filed 2025-05-08 | $13.86M derived: sum of 3 quarters · filed 2025-05-08 | $17.44M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $8.65M derived: sum of 2 quarters · filed 2025-02-28 | $12.23M derived: sum of 3 quarters · filed 2025-02-28 | $13.91M 10-K · filed 2025-02-28 |
| 2023-09-30 | $4.22M 10-Q · filed 2024-11-12 | $7.80M derived: sum of 2 quarters · filed 2024-11-12 | $9.48M 10-Q · filed 2024-11-12 | $12.05M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.58M 10-Q · filed 2024-08-08 | $5.26M 10-Q · filed 2024-08-08 | $7.84M derived: sum of 3 quarters · filed 2024-08-08 | $9.26M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.68M 10-Q · filed 2024-05-10 | $4.25M derived: sum of 2 quarters · filed 2024-05-10 | $5.67M derived: sum of 3 quarters · filed 2024-05-10 | $7.02M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $3.99M derived: sum of 2 quarters · filed 2024-03-01 | $5.34M derived: sum of 3 quarters · filed 2024-03-01 | $6.46M 10-K · filed 2024-03-01 |
| 2022-09-30 | $1.42M 10-Q · filed 2023-11-03 | $2.76M derived: sum of 2 quarters · filed 2023-11-03 | $3.88M 10-Q · filed 2023-11-03 | $4.99M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $1.34M 10-Q · filed 2023-08-07 | $2.47M 10-Q · filed 2023-08-07 | $3.58M derived: sum of 3 quarters · filed 2023-08-07 | $3.91M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $1.12M 10-Q · filed 2023-05-11 | $2.23M derived: sum of 2 quarters · filed 2023-05-11 | $2.57M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.45M derived: sum of 2 quarters · filed 2023-03-09 | $1.75M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $339.00K 10-Q · filed 2022-11-14 | $639.00K 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $391.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |